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Zika  virus  infection  during  pregnancy  poses  a  serious  risk  for pregnant  women  as it can  cause  severe  birth
defects.  Even  though  the virus  is  mainly  transmitted  via  mosquitos,  human-to-human  transmission  has
been described.  Infectious  viral  particles  have  been  detected  in breast  milk  of  infected  women  which
raised  concerns  regarding  the  safety  of breastfeeding  in  areas  of  Zika  virus  transmission  or in  case  of  a
suspected  or  conﬁrmed  Zika  virus  infection.  In this  study,  we  show  that Zika  virus  is effectively  inactivated
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Zika virus (ZIKV) infections have been declared to be a Public
ealth Emergency of International Concern on 1st of February 2016
y the World Health Organization (WHO) (WHO, 2016a). The virus
as originally discovered in 1947 in Uganda, however; it received
ittle attention until 2007 and 2013/2014 when a large outbreak
as identiﬁed in Micronesia and French Polynesia, respectively
Duffy et al., 2009; Cao-Lormeau et al., 2016). Most importantly,
uring this and later outbreaks in Brazil, neurological complica-
ions including an increased incidence of Guillain–Barré syndrome
nd fetal microcephaly were observed and could be linked to the
nfection (Cao-Lormeau et al., 2016; Brasil et al., 2016). Since then,
he virus was able to spread rapidly and by now 70 countries and
erritories have reported cases of ZIKV infection (WHO, 2016b).
ransmission occurs mainly through mosquitos, with the most
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/).important and common vectors for ZIKV being Aedes mosquitoes.
However, other modes of transmission, including sexual transmis-
sion have been implicated (Lessler et al., 2016; Arsuaga et al., 2016).
Infection poses a serious risk especially for pregnant women, as
congenital anomalies can occur in the fetus through trans-placental
transmission (Schuler-Faccini et al., 2016). Notably, ZIKV RNA has
been detected in breast milk of infected mothers and the virus has
been found to be infectious in cell culture (Dupont-Rouzeyrol et al.,
2016; Besnard et al., 2014). These ﬁndings raised questions regard-
ing the safety of breastfeeding in areas of ZIKV transmission. In June
2016, the WHO  has published a guideline summarizing the current
evidence regarding the risk of ZIKV transmission via breastfeed-
ing in which mothers with suspected, probable or conﬁrmed ZIKV
infection are encouraged to breastfeed their children, as the ben-
eﬁcial effects of breastfeeding preponderate any potential risk of
ZIKV transmission via breast milk (WHO  Geneva, 2016). Here, we
aimed to elucidate the stability and inactivation of infectious ZIKV
in human breast milk.
To this end, we collected milk samples from three healthy
human donors after ethical approval by the ethics commission of
Hanover Medical School, Hanover, Germany. All mothers provided
written informed consent for the collection of samples and sub-
sequent analysis. Milk was collected freshly and stored at −80 ◦C
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Fig. 1. Inactivation of ZIKV in human breast milk. (A) The African lineage strain of ZIKV and circulating strain from Puerto Rico were mixed at a ratio of 1:10 with human
breast  milk from three healthy donors (milk #1–3) or as control with cell culture medium. The mixture was  used to infect Vero B4 cells in a limiting dilution assay and viral
titers  were determined as TCID50/ml  72 h post infection. Samples were used directly in infection experiments (t = 0) or stored for up to 5 days at 4 ◦C before titration. Dashed
line  indicates the detection limit. Depicted are the means + SD from three individual experiments. (B) ZIKV and milk/medium were mixed as described above. Samples were




























dept  at room temperature (RT) or 63 C for 30 min  before viral titers were determin
eans  + SD from three individual experiments, n.d. not detected.
ntil further use. To analyze viral stability in human breast milk,
e incubated the African lineage strain of ZIKV (MP-7501) or the
irculating strain from Puerto Rico (PRVABC59) at a ratio of 1:10
corresponding to 1.11 × 106 TCID50/mL) with human breast milk
r as control cell culture medium (Dulbecco’s modiﬁed minimal
ssential medium (DMEM); Life Technologies, supplemented with
 mM l-glutamine (Invitrogen), non-essential amino acids (Invit-
ogen), 100 g/mL streptomycin (Invitrogen), 100 IU/mL penicillin
Invitrogen), and 10% fetal bovine serum). The low passage African
ineage strain of ZIKV (MP-7501) and circulating strain from Puerto
ico (PRVABC59) have been obtained from Culture Collections of
ublic Health England (UK) and passaged twice on A. albopictus
6/36. We  either immediately infected 1 × 104 Vero B4 cells (kindly
rovided by M.  Müller, University of Bonn Medical Centre) with
he virus/milk mixture in a limiting dilution assay or stored the
ixed samples at 4 ◦C for several days before virus titration. Virus
iter was determined as Tissue Culture Infectious Dose 50 (TCID50)
2 h post infection by ZIKV-speciﬁc immunostaining. Brieﬂy, cells
ere washed with PBS, ﬁxed for 10–20 min  with 4% PFA, and
ashed with PBS containing 0.1% saponin. Cells were incubated
ith primary mouse anti-ﬂavivirus group antigen 4G2 antibody
ATCC HB-112) in 0.3% saponin for 45 min  at 37 ◦C before wash-
ng and addition of HRP-conjugated rabbit anti-mouse antibody
Dako) for 45 min  at 37 ◦C. 3-amino-9-ethylcarbazol (AEC) sub-
trate was added for 15 min  at RT and the viral titer was determined.
s depicted in Fig. 1A, we found a reduction of viral titers in a time-
ependent manner starting with one day of storage. After 1–3 days limiting dilution assay. Dashed line indicates the detection limit. Depicted are the
(depending on the donor), virus became inactivated and viral infec-
tivity was  no longer detectable (Fig. 1A). No differences regarding
viral stability could be observed between the different ZIKV strains.
Importantly, virus remained stable for up to 5 days in cell culture
medium indicating that human breast milk inactivates ZIKV in a
time-dependent manner (Fig. 1A). We  further aimed to explore
easy and cost-effective measures to rapidly inactivate infectious
viral particles in contaminated breast milk samples. Pasteurization
of raw milk has been described to constitute an effective method
to prevent disease outbreaks (Lucey, 2015). To test the effect of
milk pasteurization on ZIKV stability, we  mixed virus with milk
or as control cell culture medium at a ratio of 1:10 before heating
the samples at 63 ◦C or keeping them at room temperature (RT)
for 30 min. Pasteurization of milk or medium reduced ZIKV infec-
tivity below the limit of detection, independent of the milk donor
or virus strain (Fig. 1B). These results imply that administration of
milk pasteurization prior infant feeding might help to prevent viral
transmission in cases of doubt. In conclusion, we demonstrate that
ZIKV can be efﬁciently inactivated in human breast milk. Two case-
report studies, analyzing three mother-infant pairs, have provided
evidence regarding the presence of ZIKV in breast milk samples
of infected women, with one study demonstrating that viral par-
ticles are infectious in cell culture (Dupont-Rouzeyrol et al., 2016;
Besnard et al., 2014). These ﬁndings have raised questions regard-
ing the safety of breastfeeding in the context of a ZIKV infection.
Breastfeeding is essential to the development of the infant and
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ends that women should start breastfeeding within 1 h of birth,
rrespective of a suspected, probable or conﬁrmed ZIKV infection
WHO  Geneva, 2016). To further evaluate the risk of a potential
IKV transmission via breastfeeding, we analyzed the stability of
IKV in breast milk. We  demonstrate that human breast milk is
ble to inactivate ZIKV in a time-dependent manner. It has been
escribed before that human breast milk acts antiviral against sev-
ral enveloped viruses (Pfaender et al., 2013). This effect seems to
e dependent on free fatty acids which are released upon storage
y milk lipases in a time-dependent manner and which incor-
orate into the viral envelope thereby destroying viral integrity
Pfaender et al., 2013). Likely, the same principle is true for the
bserved effects on ZIKV. Most importantly, this process mimics
he natural digestion of breastmilk upon which free fatty acids are
eleased in the stomach of the infant (Hamosh et al., 1985). Next
o the direct antiviral effect of stored milk, Holder pasteurization
62.5 ◦C for 30 min) offers the opportunity to inactivate poten-
ial viral contaminants, while maintaining the important bioactive
actors of milk. This includes the inactivation of human immun-
deﬁciency virus, human T-lymphoma virus, and cytomegalovirus,
ut also tuberculosis and other bacterial contaminants (Tully et al.,
001). We  tested the effect of pasteurization on ZIKV infectivity
nd found that virus was effectively inactivated by milk pasteur-
zation. We  thereby present an easy and cost-effective approach
o inactivate potential infectious viral particles in the breastmilk
o prevent a possible transmission via breastfeeding in cases of
oubt.
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